PMID- 31028199
OWN - NLM
STAT- MEDLINE
DCOM- 20190820
LR  - 20211204
IS  - 1791-7549 (Electronic)
IS  - 0258-851X (Print)
IS  - 0258-851X (Linking)
VI  - 33
IP  - 3
DP  - 2019 May-Jun
TI  - CCL21 Induces mTOR-dependent MALAT1 Expression, Leading to Cell Migration in 
      Cutaneous T-Cell Lymphoma.
PG  - 793-800
LID - 10.21873/invivo.11541 [doi]
AB  - BACKGROUND: Mycosis fungoides (MF) is indolent, but may disseminate to leukemia. 
      We reported that C-C motif chemokine ligand 21 (CCL21) is associated with MF 
      invasion and progression. Metastasis-associated lung adenocarcinoma transcript 1 
      (MALAT1), a long noncoding RNA, is associated with several cancer types, however, 
      how it interacts with CCL21 to regulate MF progression, remains unclear. 
      MATERIALS AND METHODS: Expression of long noncoding RNAs MALAT1, antisense 
      noncoding RNA in the INK4 locus (ANRIL), Hox antisense intergenic RNA (HOTAIR), 
      highly up-regulated in liver cancer RNA (HULC), and leukemia-associated 
      non-coding insulin-like growth factor 1 receptor activator RNA 1 (LUNAR1) in 
      tissues from MF was studied using polymerase chain reaction and RNA interference 
      in MF cell line MyLa were used to address this question. RESULTS: Expression of 
      MALAT1 was selectively increased in MF tissues. C-C Chemokine receptor type 7 
      (CCR7) expression was found to be increased in MyLa cells. CCL21 was found not 
      only to mediate migration, but also to enhance MALAT1 and mammalian target of 
      rapamycin (mTOR) activation in MyLa cells. Knockdown of MALAT1 abrogated 
      CCL21-mediated migration, but not mTOR activation. In contrast, mTOR inhibition 
      reduced CCL21-mediated migration and MALAT1 expression. CONCLUSION: CCL21 induced 
      mTOR activation in MyLa cells, followed by expression of MALAT1, causing cell 
      migration. MALAT1 and mTOR are potential therapeutic targets for MF.
CI  - Copyright(c) 2019, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Hong, Chien-Hui
AU  - Hong CH
AD  - Department of Dermatology, Kaohsiung Veterans General Hospital, Kaohsiung, 
      Taiwan, R.O.C.
AD  - Department of Dermatology, National Yang-Ming University College of Medicine, 
      Taipei, Taiwan, R.O.C.
FAU - Lin, Shang-Hung
AU  - Lin SH
AD  - Department of Dermatology, Kaohsiung Chang-Gung Memorial Hospital and Chang Gung 
      University College of Medicine, Kaohsiung, Taiwan, R.O.C.
FAU - Lee, Chih-Hung
AU  - Lee CH
AD  - Department of Dermatology, Kaohsiung Chang-Gung Memorial Hospital and Chang Gung 
      University College of Medicine, Kaohsiung, Taiwan, R.O.C. dermlee@gmail.com.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - In Vivo
JT  - In vivo (Athens, Greece)
JID - 8806809
RN  - 0 (CCL21 protein, human)
RN  - 0 (Chemokine CCL21)
RN  - 0 (MALAT1 long non-coding RNA, human)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (RNA, Small Interfering)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
MH  - Biopsy
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Chemokine CCL21/*metabolism
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lymphoma, T-Cell, Cutaneous/*genetics/*metabolism/pathology
MH  - Phosphorylation
MH  - RNA, Long Noncoding/*genetics
MH  - RNA, Small Interfering/genetics
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC6559909
OTO - NOTNLM
OT  - MALAT1
OT  - Mycosis fungoides
OT  - lncRNA
OT  - mTOR
OT  - migration
COIS- The Authors declare that they have no competing interests in regard to this 
      study.
EDAT- 2019/04/28 06:00
MHDA- 2019/08/21 06:00
PMCR- 2019/05/03
CRDT- 2019/04/28 06:00
PHST- 2019/01/04 00:00 [received]
PHST- 2019/01/28 00:00 [revised]
PHST- 2019/01/30 00:00 [accepted]
PHST- 2019/04/28 06:00 [entrez]
PHST- 2019/04/28 06:00 [pubmed]
PHST- 2019/08/21 06:00 [medline]
PHST- 2019/05/03 00:00 [pmc-release]
AID - 33/3/793 [pii]
AID - 10.21873/invivo.11541 [doi]
PST - ppublish
SO  - In Vivo. 2019 May-Jun;33(3):793-800. doi: 10.21873/invivo.11541.